<List><item><source>MED</source><extId>23493880</extId><pmcid>PMC3595639</pmcid><annotations><annotation><prefix> dimethyl fumarate (</prefix><exact>NCT00420212</exact><postfix>) and laquinimod (NC</postfix><tags><tag><name>NCT00420212</name><uri>http://identifiers.org/clinicaltrials/NCT00420212</uri></tag></tags><id>http://europepmc.org/articles/PMC3595639#europepmc-1562e3b95f2bf46962ce8e0c7f5f40f6</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>12) and laquinimod (</prefix><exact>NCT01047319</exact><postfix>); and the monoclona</postfix><tags><tag><name>NCT01047319</name><uri>http://identifiers.org/clinicaltrials/NCT01047319</uri></tag></tags><id>http://europepmc.org/articles/PMC3595639#europepmc-7ccd61cad33646a0693173566f8b9d30</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ibodies daclizumab (</prefix><exact>NCT01064401</exact><postfix>), rituximab (NCT000</postfix><tags><tag><name>NCT01064401</name><uri>http://identifiers.org/clinicaltrials/NCT01064401</uri></tag></tags><id>http://europepmc.org/articles/PMC3595639#europepmc-dde4f0117f42c2323188b98bfa76b587</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>064401), rituximab (</prefix><exact>NCT00087529</exact><postfix>), and alemtuzumab (</postfix><tags><tag><name>NCT00087529</name><uri>http://identifiers.org/clinicaltrials/NCT00087529</uri></tag></tags><id>http://europepmc.org/articles/PMC3595639#europepmc-3eba5a603752accbb9154933a7c26f25</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>imab (NCT00087529), and alemtuzumab (</prefix><exact>NCT00548405</exact><postfix>). </postfix><tags><tag><name>NCT00548405</name><uri>http://identifiers.org/clinicaltrials/NCT00548405</uri></tag></tags><id>http://europepmc.org/articles/PMC3595639#europepmc-30b519b6e3e7741a6b2b53a0a77850cb</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>